Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.
about
Astrocyte elevated gene-1 (AEG-1): A multifunctional regulator of normal and abnormal physiologyThe proteasome inhibitor MG-132 sensitizes PC-3 prostate cancer cells to ionizing radiation by a DNA-PK-independent mechanism.Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapyA phase 1-2, prospective, double blind, randomized study of the safety and efficacy of Sulfasalazine for the treatment of progressing malignant gliomas: study protocol of [ISRCTN45828668].Novel strategies to target the ubiquitin proteasome system in multiple myelomaRecent advancements of bortezomib in acute lymphocytic leukemia treatmentAdvances in the understanding of mechanisms and therapeutic use of bortezomibBoron chemicals in diagnosis and therapeuticsModification by ubiquitin-like proteins: significance in apoptosis and autophagy pathwaysTargeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategiesMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingTo NFκB or not to NFκB: The Dilemma on How to Inhibit a Cancer Cell Fate RegulatorBortezomib is cytotoxic to the human growth plate and permanently impairs bone growth in young miceThe proteasome inhibitor MG-132 protects hypoxic SiHa cervical carcinoma cells after cyclic hypoxia/reoxygenation from ionizing radiationThe role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders.Proteasome proteolysis supports stimulated platelet function and thrombosisTargeting the UPS as therapy in multiple myeloma.A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.Role of oxidative stress and intracellular glutathione in the sensitivity to apoptosis induced by proteasome inhibitor in thyroid cancer cells.Improved response rates with bortezomib in relapsed or refractory multiple myeloma: an observational study in Chinese patients.Nanodelivery in airway diseases: challenges and therapeutic applications.Towards Selective Mycobacterial ClpP1P2 Inhibitors with Reduced Activity against the Human Proteasome.Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells.Inhibition of Neddylation Modification Sensitizes Pancreatic Cancer Cells to Gemcitabine.26S proteasome activity is down-regulated in lung cancer stem-like cells propagated in vitro.Antileukemic activity and mechanism of drug resistance to the marine Salinispora tropica proteasome inhibitor salinosporamide A (Marizomib).Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targetsRecurrent Respiratory Papillomatosis (RRP)-Juvenile Onset.Chronic inflammation and cancer: potential chemoprevention through nuclear factor kappa B and p53 mutual antagonismTotal cost comparison in relapsed/refractory multiple myeloma.Wallerian degeneration, wld(s), and nmnat.A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.Identification and mechanistic studies of a novel ubiquitin E1 inhibitor.Development of PEGylated PLGA nanoparticle for controlled and sustained drug delivery in cystic fibrosisThe ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsAn open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.Inhibition of Siah ubiquitin ligase function.
P2860
Q24616987-BC71CBE6-78A6-4B8B-B223-17B247FB46E6Q24813108-CF74436B-15A2-4633-8271-3B67E418AEDFQ24814325-921FF395-CC46-45F9-9547-3CF1D32EE34AQ25257862-5EA6916E-6783-41D5-AF10-08714F8B398EQ26773246-DEEE990F-B1F4-4985-A5B2-30DC4156060CQ26829613-047D896D-659F-4A2E-AC7D-8C49549B6A6DQ26849940-5860706D-2518-4D7F-908B-B30A739656C3Q27006075-7EAA941D-C8BF-420F-939B-4E47667DF389Q27011543-2F982C4E-FA7C-4460-8D0D-D25B8C1DE142Q27026951-C2E989C2-40E6-439F-AD3E-2623B705F48DQ28082335-2D012346-2838-483D-BE53-24B367404E83Q28386593-53B569EA-E3ED-430F-80FB-108937BD5206Q28485441-C3E84C69-9AB8-40DF-95F7-21988A1E9E7DQ28763731-8C3C43A0-49AD-4CA6-9DA9-42C8D8100D9EQ30248842-BFCAFF0A-EEBB-460C-AD38-893471CAAAB7Q30580785-232AD69F-2DF9-4BF7-BB9D-4972C2B24D7CQ33384287-ECB9CC49-8FE2-457F-8B4D-FC387BDBE8DDQ33390287-5DC1E7D6-D8E1-440F-A236-E2D09F6153B2Q33402536-5ABA8827-F133-4DC0-A72C-C295ED5C4291Q33409161-3AA865A2-6033-48BC-AFF0-3C98AD40D67FQ33418300-C723BD17-7B7D-47ED-9381-94C2963F8DBFQ33483926-406430FD-A0D5-4760-8C49-887B0C309B57Q33601825-FD4764D8-ECDC-4C4F-AB60-5D6A2EE88A21Q33627051-76DD5E24-1B7C-4F32-9215-4BA4D9622489Q33627312-A0798A64-B524-403F-B87F-8CCED96C344FQ33655371-04FAC080-5C15-49A8-91E2-33BB0DC583E4Q33714709-C05760B4-CCCD-4328-8329-E7755AC3D010Q33719257-B7BF4DD7-D92A-43B3-AF56-5A9F4A4AAFAFQ33742779-4914258F-294F-4A5A-AA87-A1BBD4C76347Q33862782-B8FADD39-37A4-4F45-8D4C-59BBB21997EDQ34011058-90B79860-3FD5-42E4-8226-B3299D5CC8D5Q34079481-B505A39A-28F5-4D3D-B3F9-B39781142030Q34088340-4585AB68-5A4C-473D-A575-03570CDFE6FCQ34106847-594EEDD1-8B62-4731-9A3D-E504686D7FDAQ34134986-32852C77-370A-4233-AC8E-B253F0B48940Q34139564-D0E7AEDE-9021-48A3-B466-643FF3509A25Q34198852-ABF52FD1-110A-4DA7-BBC7-CE8CF590E8DFQ34218976-28A704F9-FD2C-4BA9-BCC1-FEB7648079E2Q34291281-97EF6559-C5B8-423E-AF9D-95ED11553F48Q34400571-07D7B343-A283-4DF6-82BC-8C545284A391
P2860
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Velcade: U.S. FDA approval for ...... progressing on prior therapy.
@ast
Velcade: U.S. FDA approval for ...... progressing on prior therapy.
@en
type
label
Velcade: U.S. FDA approval for ...... progressing on prior therapy.
@ast
Velcade: U.S. FDA approval for ...... progressing on prior therapy.
@en
prefLabel
Velcade: U.S. FDA approval for ...... progressing on prior therapy.
@ast
Velcade: U.S. FDA approval for ...... progressing on prior therapy.
@en
P2093
P1433
P1476
Velcade: U.S. FDA approval for ...... progressing on prior therapy.
@en
P2093
Ann T Farrell
Peter F Bross
Richard Pazdur
Robert C Kane
P304
P356
10.1634/THEONCOLOGIST.8-6-508
P577
2003-01-01T00:00:00Z